Last reviewed · How we verify
racemic albuterol MDI
Racemic albuterol is a beta-2 adrenergic agonist that relaxes airway smooth muscle to relieve bronchospasm and improve airflow in obstructive airway diseases.
Racemic albuterol is a beta-2 adrenergic agonist that relaxes airway smooth muscle to relieve bronchospasm and improve airflow in obstructive airway diseases. Used for Acute bronchospasm relief in asthma, Chronic obstructive pulmonary disease (COPD) maintenance and acute symptom relief.
At a glance
| Generic name | racemic albuterol MDI |
|---|---|
| Sponsor | Sumitomo Pharma America, Inc. |
| Drug class | Beta-2 adrenergic agonist (short-acting bronchodilator) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Albuterol binds to beta-2 adrenergic receptors on airway smooth muscle cells, activating intracellular signaling that increases cAMP levels and causes smooth muscle relaxation. This bronchodilation effect provides rapid relief of airway obstruction and improved breathing. The racemic formulation contains both R- and S-enantiomers, though the R-enantiomer is the pharmacologically active form.
Approved indications
- Acute bronchospasm relief in asthma
- Chronic obstructive pulmonary disease (COPD) maintenance and acute symptom relief
Common side effects
- Tremor
- Headache
- Nervousness
- Palpitations
- Tachycardia
- Muscle cramps
Key clinical trials
- A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma (PHASE2)
- Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma (PHASE3)
- Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects (PHASE2)
- Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma (PHASE2)
- Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma (PHASE2)
- A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma (PHASE2)
- Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma (PHASE3)
- Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- racemic albuterol MDI CI brief — competitive landscape report
- racemic albuterol MDI updates RSS · CI watch RSS
- Sumitomo Pharma America, Inc. portfolio CI